Seres Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 233
- Market Cap
- $126.4M
- Introduction
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04995653
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Banner Health - MD Anderson Medical Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Vancomycin Pre-TreatmentDrug: Placebo for Vancomycin Pre-TreatmentDrug: Placebo for SER-287Drug: SER-287
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT03759041
- Locations
- 🇨🇦
(Investigator site), Saskatoon, Saskatchewan, Canada
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
- Conditions
- Clostridium Difficile Infection
- Interventions
- Drug: PlaceboBiological: SER-109
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT03183128
- Locations
- 🇨🇦
(Investigator site), Chicoutimi, Quebec, Canada
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
- Conditions
- Clostridioides Difficile Infection
- Interventions
- Biological: SER-109
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 263
- Registration Number
- NCT03183141
- Locations
- 🇨🇦
(Investigator site), Sainte-Foy, Quebec, Canada
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
- Conditions
- Clostridium Difficile Infection
- Interventions
- Drug: SER-262Drug: Placebo
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02830542
- Locations
- 🇺🇸
Remington Davis, Columbus, Ohio, United States
🇺🇸North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸Lalla-Reddy Medical Corporation, Fountain Valley, California, United States
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02618187
- Locations
- 🇺🇸
Community Clinical Research Network, Marlborough, Massachusetts, United States
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
- Conditions
- Clostridium Difficile
- Interventions
- Drug: SER-109Drug: Placebo
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Seres Therapeutics, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT02437487
- Locations
- 🇺🇸
ZASA Clinical Research, Atlantis, Florida, United States
🇺🇸Omega Research Consultants LLC, DeBary, Florida, United States
🇺🇸Borland-Groover Clinic, Jacksonville, Florida, United States
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
- Conditions
- Clostridioides Difficile Infection
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Seres Therapeutics, Inc.
- Registration Number
- NCT02437500